Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
monarchE: abemaciclib with or without endocrine therapy after surgery for high-risk HR-positive, HER2-negative early breast cancer
NL-OMON59671Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Invasive disease-free survival. Started Jul 2017; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON59671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59671.